L-Type amino acid transporter 1 as a target for drug delivery.

Animals Antineoplastic Agents / chemistry Biological Transport Blood-Brain Barrier / metabolism Brain Central Nervous System / metabolism Drug Carriers Drug Delivery Systems / methods Humans Large Neutral Amino Acid-Transporter 1 / metabolism Positron-Emission Tomography
L-type amino acid transporter 1 drug delivery systems membrane transporter targeting

Journal

Pharmaceutical research
ISSN: 1573-904X
Titre abrégé: Pharm Res
Pays: United States
ID NLM: 8406521

Informations de publication

Date de publication:
06 May 2020
Historique:
received: 04 03 2020
accepted: 15 04 2020
entrez: 8 5 2020
pubmed: 8 5 2020
medline: 22 9 2020
Statut: epublish

Résumé

Our growing understanding of membrane transporters and their substrate specificity has opened a new avenue in the field of targeted drug delivery. The L-type amino acid transporter 1 (LAT1) has been one of the most extensively investigated transporters for delivering drugs across biological barriers. The transporter is predominantly expressed in cerebral cortex, blood-brain barrier, blood-retina barrier, testis, placenta, bone marrow and several types of cancer. Its physiological function is to mediate Na

Identifiants

DOI: 10.1007/s11095-020-02826-8 PMID: 32377929 PMC: PMC7203094
pubmed: 32377929
doi: 10.1007/s11095-020-02826-8
pii: 10.1007/s11095-020-02826-8
pmc: PMC7203094
doi:

Substances chimiques

Antineoplastic Agents 0
Drug Carriers 0
Large Neutral Amino Acid-Transporter 1 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

88

Subventions

Organisme : Academy of Finland
ID : 294227, 307057

Références

Invest Ophthalmol Vis Sci. 2005 Jul;46(7):2522-30
pubmed: 15980244
Eur J Nucl Med Mol Imaging. 2003 Nov;30(11):1561-7
pubmed: 14579097
Endocrinology. 2001 Oct;142(10):4339-48
pubmed: 11564694
J Neurooncol. 2013 Jan;111(1):11-8
pubmed: 23086431
Mol Pharm. 2017 Nov 6;14(11):3834-3847
pubmed: 28958145
Int J Mol Sci. 2018 Aug 12;19(8):
pubmed: 30103560
Int J Pharm. 2008 Jan 22;347(1-2):23-30
pubmed: 17686592
Bioorg Med Chem Lett. 2016 Oct 15;26(20):5000-5006
pubmed: 27624080
J Nucl Med. 2004 Sep;45(9):1591-6
pubmed: 15347729
Sci Rep. 2019 Oct 31;9(1):15718
pubmed: 31673030
Mol Cell Proteomics. 2014 Feb;13(2):397-406
pubmed: 24309898
Pharm Res. 2013 Oct;30(10):2523-37
pubmed: 24137801
J Med Chem. 2018 Aug 23;61(16):7358-7373
pubmed: 30048132
Neoplasia. 2004 Jan-Feb;6(1):74-84
pubmed: 15068672
Fluids Barriers CNS. 2015 Sep 04;12:21
pubmed: 26337286
Bioorg Med Chem Lett. 2016 Jun 1;26(11):2616-2621
pubmed: 27106710
J Cereb Blood Flow Metab. 2000 Nov;20(11):1557-62
pubmed: 11083230
Ophthalmol Eye Dis. 2010 Jul 29;2:43-56
pubmed: 23861613
Int J Mol Sci. 2018 Apr 24;19(5):
pubmed: 29695141
Sci Rep. 2019 Oct 21;9(1):15061
pubmed: 31636293
ACS Appl Mater Interfaces. 2017 Nov 15;9(45):39259-39270
pubmed: 29058874
Biochim Biophys Acta Gen Subj. 2017 Apr;1861(4):727-736
pubmed: 28088504
Int J Pharm. 2010 Oct 31;399(1-2):121-8
pubmed: 20727958
Clin Nutr. 2015 Dec;34(6):1189-94
pubmed: 25660414
Biochem Pharmacol. 2013 Jun 1;85(11):1672-83
pubmed: 23567998
Small. 2016 Oct;12(40):5633-5645
pubmed: 27571928
Pflugers Arch. 2004 Feb;447(5):532-42
pubmed: 14770310
Int J Pharm. 2002 Oct 24;247(1-2):115-25
pubmed: 12429490
Sci Rep. 2019 Sep 6;9(1):12860
pubmed: 31492955
J Nucl Med. 2012 Aug;53(8):1253-61
pubmed: 22743251
J Neurooncol. 2010 Sep;99(2):217-25
pubmed: 20091333
Cell. 2016 Dec 1;167(6):1481-1494.e18
pubmed: 27912058
Mol Aspects Med. 2013 Apr-Jun;34(2-3):139-58
pubmed: 23506863
Clin Cancer Res. 2007 Nov 1;13(21):6369-78
pubmed: 17975149
Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):1049-58
pubmed: 21570201
J Med Chem. 2008 Feb 28;51(4):932-6
pubmed: 18217702
Biochim Biophys Acta. 2002 Sep 20;1565(1):112-21
pubmed: 12225859
PLoS One. 2016 Jun 08;11(6):e0157139
pubmed: 27276226
J Control Release. 2017 Dec 10;267:15-30
pubmed: 28917530
Cancer Res. 1987 Mar 15;47(6):1571-6
pubmed: 3815357
Drug Deliv. 2016 Sep;23(7):2327-2337
pubmed: 25475953
Trends Biochem Sci. 2018 Oct;43(10):752-789
pubmed: 30177408
Bioorg Med Chem Lett. 2010 Jun 15;20(12):3688-91
pubmed: 20466543
Eur J Pharm Sci. 2019 Mar 1;129:99-109
pubmed: 30625368
Mol Pharm. 2018 Jun 4;15(6):2327-2337
pubmed: 29688723
Pharm Res. 2018 Nov 28;36(1):17
pubmed: 30488131
Physiol Rev. 1990 Jan;70(1):43-77
pubmed: 2404290
Neurochem Res. 2016 Oct;41(10):2797-2809
pubmed: 27412117
Int J Mol Sci. 2019 May 16;20(10):
pubmed: 31100853
Mol Pharm. 2011 Oct 3;8(5):1857-66
pubmed: 21770378
Mol Pharm. 2016 Jul 5;13(7):2484-91
pubmed: 27266990
J Natl Cancer Inst. 2013 Oct 2;105(19):1463-73
pubmed: 24052624
J Control Release. 2017 Sep 10;261:93-104
pubmed: 28662899
Int J Pharm. 2008 Jul 9;359(1-2):15-24
pubmed: 18472234
J Clin Pathol. 2012 Nov;65(11):1019-23
pubmed: 22813728
J Allergy Clin Immunol. 2020 Jan;145(1):199-214.e11
pubmed: 31605740
ChemMedChem. 2014 Dec;9(12):2699-707
pubmed: 25205473
Eur J Pharm Sci. 2013 Feb 14;48(3):523-31
pubmed: 23228412
J Membr Biol. 1999 Dec 1;172(3):181-92
pubmed: 10568788
Sci Rep. 2020 Jan 28;10(1):1292
pubmed: 31992742
J Neurochem. 2011 Apr;117(2):333-45
pubmed: 21291474
Nucl Med Commun. 1997 Feb;18(2):169-75
pubmed: 9076774
J Pharm Sci. 2013 Sep;102(9):3343-55
pubmed: 23650139
Pharm Res. 1988 Jun;5(6):369-71
pubmed: 3244648
NeuroRx. 2005 Jan;2(1):3-14
pubmed: 15717053
Nat Struct Mol Biol. 2019 Jun;26(6):510-517
pubmed: 31160781
Clin Cancer Res. 2005 Jun 1;11(11):3987-4002
pubmed: 15930333
Biol Pharm Bull. 2008 Nov;31(11):2126-30
pubmed: 18981585
Amino Acids. 2015 Feb;47(2):335-44
pubmed: 25385314
Biochim Biophys Acta. 2004 Aug 30;1664(2):206-16
pubmed: 15328053
Bioorg Chem. 2018 Dec;81:494-503
pubmed: 30243240
Clin Nucl Med. 2020 May;45(5):341-348
pubmed: 32049723
Cancer Res. 1990 Sep 1;50(17):5475-80
pubmed: 2386952
J Biol Chem. 1998 Sep 11;273(37):23629-32
pubmed: 9726963
Biol Pharm Bull. 2010;33(7):1250-2
pubmed: 20606323
Anticancer Res. 2010 Dec;30(12):4819-28
pubmed: 21187458
Exp Eye Res. 2013 Aug;113:135-42
pubmed: 23773890
Pflugers Arch. 2000 Aug;440(4):503-12
pubmed: 10958334
J Nucl Med. 1987 Jun;28(6):1037-40
pubmed: 3585494
Am J Physiol Endocrinol Metab. 2004 Oct;287(4):E622-9
pubmed: 15165996
Mol Pharmacol. 2002 Apr;61(4):729-37
pubmed: 11901210
Pathol Res Pract. 2008;204(8):553-61
pubmed: 18440724
Nature. 1963 Feb 23;197:765-7
pubmed: 13940861
Proc Natl Acad Sci U S A. 2013 Apr 2;110(14):5480-5
pubmed: 23509259
Intractable Rare Dis Res. 2015 Nov;4(4):165-9
pubmed: 26668776
Amino Acids. 2016 Apr;48(4):1045-1058
pubmed: 26724922
Expert Opin Drug Deliv. 2017 Jan;14(1):93-107
pubmed: 27367188
Biochim Biophys Acta. 2001 Oct 1;1514(2):291-302
pubmed: 11557028
Front Chem. 2018 Jun 22;6:243
pubmed: 29988369
Expert Opin Ther Targets. 2015;19(10):1319-37
pubmed: 25968633
World J Gastrointest Oncol. 2017 Jan 15;9(1):21-29
pubmed: 28144396
Science. 2002 Aug 16;297(5584):1116-8
pubmed: 12183610
Nature. 1998 Sep 17;395(6699):288-91
pubmed: 9751058
Cancer Sci. 2015 Jun;106(6):747-56
pubmed: 25867020
EMBO J. 2002 Feb 15;21(4):580-9
pubmed: 11847106
Nanomedicine. 2017 Apr;13(3):987-998
pubmed: 27890657
Brain Res. 2000 Oct 6;879(1-2):115-21
pubmed: 11011012
J Biol Chem. 1979 Feb 25;254(4):1057-64
pubmed: 762115
Mol Pharm. 2019 Jul 1;16(7):3261-3274
pubmed: 31180686
Drug Deliv. 2007 Jan;14(1):25-31
pubmed: 17107928
J Radiat Res. 2009 Jan;50(1):51-60
pubmed: 18957828
Neurology. 1994 Aug;44(8):1491-9
pubmed: 8058155
Int J Pharm. 2016 Feb 10;498(1-2):205-16
pubmed: 26705152
J Med Chem. 1987 Mar;30(3):542-7
pubmed: 3820226
Colloids Surf B Biointerfaces. 2016 May 1;141:260-267
pubmed: 26859117
Eur J Nucl Med Mol Imaging. 2013 Oct;40(11):1692-700
pubmed: 23801167
Eur J Nucl Med Mol Imaging. 2013 Apr;40(4):615-35
pubmed: 23232505
J Pharm Sci. 1999 May;88(5):561-7
pubmed: 10229650
Molecules. 2018 Oct 11;23(10):
pubmed: 30314360
Cancer Chemother Pharmacol. 1991;29(2):89-94
pubmed: 1760863
Cancer Sci. 2015 Mar;106(3):279-86
pubmed: 25580517
Nature. 2019 Apr;568(7750):127-130
pubmed: 30867591
Radiother Oncol. 2011 Apr;99(1):98-9
pubmed: 21397966

Auteurs

Elena Puris (E)

School of Pharmacy, University of Eastern Finland, P.O. Box 1627, FI-70211, Kuopio, Finland. elena.puris@uni-heidelberg.de.
Institute of Pharmacy and Molecular Biotechnology, Ruprecht-Karls-University, 69120, Heidelberg, Germany. elena.puris@uni-heidelberg.de.
ORCID: 0000-0002-1769-389X

Mikko Gynther (M)

School of Pharmacy, University of Eastern Finland, P.O. Box 1627, FI-70211, Kuopio, Finland.

Seppo Auriola (S)

School of Pharmacy, University of Eastern Finland, P.O. Box 1627, FI-70211, Kuopio, Finland.

Kristiina M Huttunen (KM)

School of Pharmacy, University of Eastern Finland, P.O. Box 1627, FI-70211, Kuopio, Finland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › L-Type amino acid transporter 1 as a target...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › L-Type amino acid transporter 1 as a target...
questionsmedicales.fr › Métabolisme › Transport biologique › L-Type amino acid transporter 1 as a target...
questionsmedicales.fr › Système nerveux › Système nerveux central › Encéphale › Barrière hémato-encéphalique › L-Type amino acid transporter 1 as a target...
questionsmedicales.fr › Système nerveux › Système nerveux central › Encéphale › L-Type amino acid transporter 1 as a target...
questionsmedicales.fr › Système nerveux › Système nerveux central › L-Type amino acid transporter 1 as a target...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Systèmes de délivrance de médicaments › Vecteurs de médicaments › L-Type amino acid transporter 1 as a target...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Systèmes de délivrance de médicaments › L-Type amino acid transporter 1 as a target...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › L-Type amino acid transporter 1 as a target...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Protéines de transport membranaire › Protéines transporteurs de solutés › Système Ly+ de transport d'acides aminés › Antigènes CD98 › Chaines légères de l'antigène CD98 › Transporteur-1 d'acides aminés neutres à longue chaîne › L-Type amino acid transporter 1 as a target...
questionsmedicales.fr › Diagnostic › Techniques et procédures diagnostiques › Techniques de diagnostic radioisotopique › Scintigraphie › Tomoscintigraphie › Tomographie par émission de positons › L-Type amino acid transporter 1 as a target...